Literature DB >> 32141829

Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib.

Gonçalo Nunes1, Cristina Fonseca1, Marta Patita1, Mario João Aleixo2, Miguel Ramalho3, Jorge Fonseca4.   

Abstract

Entities:  

Year:  2020        PMID： 32141829      PMCID： PMC7062131          DOI： 10.5152/tjg.2020.181044

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN： 1300-4948            Impact factor:   1.852


× No keyword cloud information.
  5 in total

Review 1.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

2.  Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.

Authors:  Leonidas Chelis; Napoleon Ntinos; Vasilios Souftas; Savas Deftereos; Nikolaos Xenidis; Elen Chamalidou; Eustratios Maltezos; Stylianos Kakolyris
Journal:  Med Oncol       Date:  2010-08-31       Impact factor: 3.064

3.  Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.

Authors:  Massimiliano Berretta; Fabrizio Di Benedetto; Luigino Dal Maso; Bruno Cacopardo; Guglielmo Nasti; Gaetano Facchini; Alessandra Bearz; Michele Spina; Elisa Garlassi; Valli De Re; Francesco Fiorica; Arben Lleshi; Umberto Tirelli
Journal:  Anticancer Drugs       Date:  2013-02       Impact factor: 2.248

4.  Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.

Authors:  Jordi Rimola; Álvaro Díaz-González; Anna Darnell; María Varela; Fernando Pons; Manuel Hernandez-Guerra; Manuel Delgado; Javier Castroagudin; Ana Matilla; Bruno Sangro; Carlos Rodriguez de Lope; Margarita Sala; Carmen Gonzalez; Carlos Huertas; Beatriz Minguez; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

5.  Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report.

Authors:  Pasquale De Nardo; Magdalena Viscione; Angela Corpolongo; Rita Bellagamba; Giovanni Vennarecci; Giuseppe Maria Ettorre; Elisa Gentilotti; Chiara Tommasi; Emanuele Nicastri
Journal:  Infect Agent Cancer       Date:  2012-06-28       Impact factor: 2.965
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.